AstraZeneca plc (AZN) Downgraded by Liberum Capital

Liberum Capital cut shares of AstraZeneca plc (LON:AZN) from a buy rating to a hold rating in a research note released on Thursday morning, MarketBeat Ratings reports. The firm currently has GBX 5,000 ($64.57) price objective on the biopharmaceutical company’s stock, up from their previous price objective of GBX 4,800 ($61.99).

AZN has been the subject of a number of other research reports. Morgan Stanley restated an overweight rating and set a GBX 5,600 ($72.32) price objective on shares of AstraZeneca plc in a research report on Friday, June 23rd. UBS AG set a GBX 4,550 ($58.76) price objective on AstraZeneca plc and gave the company a neutral rating in a research report on Thursday, August 31st. Deutsche Bank AG restated a buy rating on shares of AstraZeneca plc in a research report on Monday, May 22nd. Jefferies Group LLC boosted their price objective on AstraZeneca plc from GBX 4,350 ($56.18) to GBX 4,800 ($61.99) and gave the company a hold rating in a research report on Monday, September 11th. Finally, Shore Capital restated a hold rating on shares of AstraZeneca plc in a research report on Tuesday, August 29th. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and nine have issued a buy rating to the stock. The company currently has a consensus rating of Hold and an average target price of GBX 5,022.91 ($64.87).

Shares of AstraZeneca plc (AZN) opened at 4719.50 on Thursday. The stock’s 50 day moving average price is GBX 4,556.15 and its 200 day moving average price is GBX 4,880.61. AstraZeneca plc has a 1-year low of GBX 3,996.00 and a 1-year high of GBX 5,520.00. The stock’s market cap is GBX 59.75 billion.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece can be viewed at https://transcriptdaily.com/2017/09/17/astrazeneca-plc-azn-downgraded-by-liberum-capital.html.

The business also recently announced a dividend, which was paid on Monday, September 11th. Stockholders of record on Thursday, August 10th were given a dividend of GBX 68.90 ($0.89) per share. This represents a dividend yield of 1.35%. The ex-dividend date of this dividend was Thursday, August 10th.

In related news, insider Nazneen Rahman bought 39 shares of the business’s stock in a transaction dated Thursday, July 27th. The shares were bought at an average cost of GBX 4,370 ($56.44) per share, with a total value of £1,704.30 ($2,201.08).

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply